Division Director Clinical Pharmacology & Toxicology Children'S Mercy Kansas , Mo

The Department of Pediatrics at Childrens Mercy seeks a creative and scholarly leader
to serve as Division Director of Clinical Pharmacology, Toxicology, and Therapeutic
Innovation. The Division Director will be responsible for leading the research, educational,
and quality missions of Clinical Pharmacology, an academic division focused on providing
clinical consultation and research programs aimed at making the use of medications in
children safer and more effective. Within the division, the Section of Medical Toxicology
provides consultative services for potential poison exposures, including overdoses,
environmental exposures, and envenomations. The Division Director will foster
collaborative ties throughout Childrens Mercy, bridging the divisions research missions
in genomic, clinical research, and translational interests across the Department of
Pediatrics and CMRI.

This is a faculty position offering academic appointments at the University of Missouri
- Kansas City School of Medicine and the Kansas University School of Medicine, rank to
be commensurate with experience. Kansas City's strong culture of philanthropy has led
to the creation of many endowed roles available to distinguished and accomplished
leaders. An endowed position may be extended to the selected candidate, contingent
upon their qualifications and record of achievement.

Established in 1996, Clinical Pharmacology has a national and international reputation
for impactful translational science and excellence in training. The Division has a strong
record for successful extramural funding and an outstanding publication record. Clinical
Pharmacology faculty and staff are national leaders in pharmacogenetics, institutional
leaders in health equity research, and outstanding clinicians, using pharmacology and
toxicology to improve the care of patients. Among the groups in the Division are:

GOLDILOKs Clinic (GOLDILOKS stands for Genomic- and Ontogeny Linked Dose Individualization and cLinical Optimization for KidS.) is a
multidisciplinary clinic with a pediatrician, clinical pharmacist, and nurse who see
patients with a variety of conditions including adverse drug reactions, drug-drug
interactions, and medication nonresponse. Additionally, the clinical staff meet
weekly with genetics lab experts and a social worker to discuss upcoming patients
and formulate a multidisciplinary care plan individualized to each patient. The clinic
offers educational opportunities to pharmacy students, medical students,
residents, and fellows.

The Medical Toxicology Consult Team provides consultative services for a variety
of environmental, exposure, overdose and poison issues. A Children's Mercy
Medical Toxicologist is on call 24 hours a day, seven days a week. Our
toxicologists also provide medical direction for the Kansas Poison Control Center.
This service on average has 150-200 beside consults per year. Academically, the
toxicologists provide lectures to CMH Pediatric Emergency Medicine fellows and
residents, CMH Pediatric Medicine fellows, TMC/University Health Emergency
Medicine residents, and 5th/6th year UMKC medical students. In continuing the
collaboration of research, Kansas Fights Addiction Grant-Opioid Withdrawal
Treatment Clinical Practice Guideline was rewarded.

Childrens Mercy Hospital (CMH) Pediatric Clinical Pharmacology (T32) training
program is the Division of Clinical Pharmacology and Toxicology at CMH one of
the largest and most comprehensive Pediatric Clinical Pharmacology programs in
North America. Our fellowship training program is accredited by the American
Board of Clinical Pharmacology (ABCP) and has formally trained 31 fellows since
1998 (21 pediatricians, 6 pharmacists, 1 advanced practice nurse, 3 PhD
scientists).

The drug biotransformation core serves to characterize drug disposition pathways
along with the consequences of drug metabolizing enzyme (DME) polymorphisms
in subcellular systems derived from pediatric tissues. A cell culture facility permits
fellows and faculty to explore the regulation and expression of DME related
proteins. A robust analytical core supports in vitro and in vivo pharmacology- and
metabolomics-related research, emphasizing the characterization of
developmental trajectories of drug disposition and response pathways.

Partnerships with University of Kansas Nuclear Magnetic Resonance (NMR)
spectroscopy core allow for the characterization of drug metabolites or biomarker
development. The Analytical Chemistry Core Director can provide both didactic
and hands-on instruction to our trainees on quantitative pharmacology methods.

We have an internationally recognized pharmacogenetics/genomics (PGx)
program defining gene sequence variations related to drug disposition and action.
This program also administers the Pharmacogene Variation (Pharm Var)
Consortium. The Pharmacogene Variation (Pharm Var) Consortium is a globally
recognized central repository for pharmacogene (PGx) variation. The major focus
of Pharm Var is to catalogue allelic variation of genes impacting drug…